Metraipolis › archive › dc_89be3479e7e5

Advancing Alzheimer's Disease Treatment: Synergistic Ligand Combinations Targeting BACE1 via Multi-Ligand Simultaneous Docking — arXiv:2609.04301

Source
arXiv (en)
Original
https://arxiv.org/abs/2609.04301
License (as archived)
CC0-1.0
Archived
2026-10-17T00:28:23.540Z
SHA-256 of the archived text
c915cd0093396a51f35c0b60621b0f5364a53065925d632a2fe693f390d08762
Stable URL of this page
https://metraipolis.com/documento/dc_89be3479e7e5

How to cite

Advancing Alzheimer's Disease Treatment: Synergistic Ligand Combinations Targeting BACE1 via Multi-Ligand Simultaneous Docking — arXiv:2609.04301 — arXiv (en), https://arxiv.org/abs/2609.04301 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_89be3479e7e5 (Metraipolis archive dc_89be3479e7e5, sha256 c915cd0093396a51f35c0b60621b0f5364a53065925d632a2fe693f390d08762)
BibTeX
@misc{dc89be3479e7e5,
  title = {Advancing Alzheimer's Disease Treatment: Synergistic Ligand Combinations Targeting BACE1 via Multi-Ligand Simultaneous Docking — arXiv:2609.04301},
  howpublished = {arXiv (en)},
  url = {https://arxiv.org/abs/2609.04301},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_89be3479e7e5; sha256 c915cd0093396a51f35c0b60621b0f5364a53065925d632a2fe693f390d08762},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2609.04301. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes, primarily affecting the elderly. Current treatments focus on symptom management as no therapies effectively halt or reverse disease progression. Newer therapies targeting BACE1, a key enzyme in amyloid plaque formation, have shown promise in clinical trials, though they have been limited by side effects and insufficient efficacy in slowing cognitive decline. This is the first study where multi-ligand simultaneous docking (MLSD) was employed to identify potential synergistic inhibitor combinations from among thousands of small molecules that could yield better results than the current phase-III inhibitors of BACE1. The recent phase III drugs such as Atabecestat, Elenbecestat, Lanabecestat, and Verubecestat were considered to be standards for comparison in this study. A library of small molecules with known IC50 values against BACE1 was filtered for flagging Pan-Assay Interference (PAINS) and "Brenk" compounds. Single-ligand docking revealed individual ligand interactions with the protein, forming the basis for creating ligand pairs tested in MLSD. Among these combinations, CHEMBL4078427 and CHEMBL3656158, CHEMBL4078427 and CHEMBL3695732, Verubecestat and CHEMBL3656158, and CHEMBL4078427 and Lanabecestat demonstrated excellent binding affinity of -19.90 kcal/mol, -18.45 kcal/mol, -18.07 kcal/mol, and -17.67 kcal/mol with the protein, which is significantly greater than those of phase-III inhibitors, along with inter-ligand interactions indicative of a synergistic effect. These findings underscore the transformative potential of MLSD in identifying synergistic compound interactions, paving the way for novel combination therapies in the treatment of Alzheimer's disease.

Tema degli esploratori: scienze della vita e salute (retro-catalogo arXiv: annunci del 2026-09-07 in q-bio.BM).
Categorie arXiv: Biomolecules (q-bio.BM).
Pagina del lavoro: https://arxiv.org/abs/2609.04301 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina.
Letto il 2026-10-17T00:10:43.391Z dalla pagina https://arxiv.org/catchup/q-bio.BM/2026-09-07?abs=True (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).